Ascendis Pharma 2025 Revenue Surges 97% to €720 Million
Ascendis Pharma's 2025 revenue surged 97% to €720 million, with Q4 driving an operating profit of €10 million and €73 million in operating cash flow. YORVIPATH generated €477 million and SKYTROFA €206 million, while the year-end cash position reached €616 million, bolstered by a $100 million Novo Nordisk payment.
1. Revenue and Operating Results
The company nearly doubled its total revenue in 2025 to €720 million, achieving an operating profit of €10 million and generating €73 million in operating cash flow during the fourth quarter.
2. Product Growth Drivers
YORVIPATH led revenue with €477 million for the year, while SKYTROFA contributed €206 million and secured a 45% share of the US long-acting growth hormone market.
3. Financial Position and Pipeline
Despite a full-year net loss of €228 million driven by commercial investments, the company closed 2025 with €616 million in cash, including a $100 million partnership payment, and is preparing for a PDUFA decision on TransCon CNP for pediatric achondroplasia on February 28 2026.